<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03775902</url>
  </required_header>
  <id_info>
    <org_study_id>NAK-KATP</org_study_id>
    <nct_id>NCT03775902</nct_id>
  </id_info>
  <brief_title>Regulation of KATP Channels and Na+/K+ ATPase in Relation to Fatigue Development</brief_title>
  <official_title>Regulation of KATP Channels and Na+/K+ ATPase in Relation to Fatigue Development in Healthy and Insulin Resistant Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Copenhagen</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the role of ATP sensitive K+ potassium channels and the Na+/K+ pump in the
      development of fatigue in healthy and in pre/diabetic subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 19, 2018</start_date>
  <completion_date type="Actual">January 1, 2020</completion_date>
  <primary_completion_date type="Actual">January 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Extracellular potassium concentration meassured with microdialysis</measure>
    <time_frame>Changes in potassium handling from the placebo experimental day compared to the experimental days with Nicorandil or Glibenclamide ingestion with 14 days between each experimental day. Timeframe pr. subject approx. 6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Performance (time to exhaustion) during knee extensor exercise</measure>
    <time_frame>Changes in performance during the placebo experimental day compared to the experimental days with Nicorandil or Glibenclamide ingestion with 14 days between each experimental day. Timeframe pr. subject approx. 6 weeks.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Healthy subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three experimental day where the effect of Nicorandil (20mg), Glibenclamide (3,5mg) or placebo will asses the function of the ATP sensitive potassium pumps role in the development of fatigue.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pre and/or type 2 diabetics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three experimental day where the effect of Nicorandil (20mg), Glibenclamide (3,5mg) or placebo will asses the function of the ATP sensitive potassium pumps role in the development of fatigue.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo, Nicorandil, Glimepiride</intervention_name>
    <description>On three separate experimental days, one of the two drugs or placebo is administered in tablet form.</description>
    <arm_group_label>Healthy subjects</arm_group_label>
    <arm_group_label>Pre and/or type 2 diabetics</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non smokers

          -  HbA1c &lt;38mmol/mol and &gt;42 mmol/mol

          -  VO2max &lt;40 ml/kg/min

          -  BMI &gt;26 kg/m2

        Exclusion Criteria:

          -  Use of antidiabetic medication

          -  Allergy towards Nicorandil of Glimepiride

          -  Chronic disease other than type 2 diabetes
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <state>Danmark</state>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 4, 2018</study_first_submitted>
  <study_first_submitted_qc>December 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2018</study_first_posted>
  <last_update_submitted>January 20, 2020</last_update_submitted>
  <last_update_submitted_qc>January 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Copenhagen</investigator_affiliation>
    <investigator_full_name>Morten Hostrup, PhD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicorandil</mesh_term>
    <mesh_term>Glimepiride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

